"目录号: HY-14814
Anti-infection-
Delafloxacin (RX-3341, ABT-492)是氟喹诺酮类抗生素。
Bacterial
相关产品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-
生物活性
Description
Delafloxacin (RX-3341, ABT-492) is a fluoroquinolone antibiotic agent.IC50 Value: MICs ranging from 0.0078 to 0.125 micro g/ml for levofloxacin-resistant Streptococcus pneumoniae strains [1]Target: AntibacterialABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms.in vitro: ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015 [2]. ABT-492 was as active as trovafloxacin against Chlamydia trachomatis, indicating good intracellular penetration and antibacterial activity [3].in vivo: Clinical trial: N/A
Clinical Trial
NCT02505997
Melinta Therapeutics, Inc.
VA Drug Interactions
June 2015
Phase 1
NCT02245243
Melinta Therapeutics, Inc.
Hepatic Impairment
September 2014
Phase 1
NCT02679573
Melinta Therapeutics, Inc.
Community Acquired Bacterial Pneumonia
December 14, 2016
Phase 3
NCT02015637
Melinta Therapeutics, Inc.
Gonorrhea
January 2014
Phase 3
NCT01984684
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections-Skin Structures and Soft Tissue Infections
May 2014
Phase 3
NCT01811732
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections
April 2013
Phase 3
NCT01283581
Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections
January 2011
Phase 2
NCT00719810
Melinta Therapeutics, Inc.
Skin Structure Infections-Bacterial Skin Diseases-Staphylococcal Skin Infections
June 2008
Phase 2
View MoreCollapse
References
[1].Gunderson SM, Hayes RA, Quinn JP, In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2004 Jan;48(1):203-8.
[2].Goldstein EJ, Citron DM, Merriam CV, In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother. 2003 Sep;47(9):3008-11.
[3].Nilius AM, Shen LL, Hensey-Rudloff D, In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9.